Altimmune (ALT) Restructuring Costs (2015)

Altimmune's (ALT) quarterly Restructuring Costs came in at $26886.0 in Q4 2015, down 93.64% on a QoQ basis from $422482.0 in Q3 2015.

Altimmune (ALT) Restructuring Costs (2015) Analysis & Trends

Altimmune (ALT) has 1 years of Restructuring Costs data on file, last reported at $26886.0 in Q4 2015.

On a quarterly basis, Restructuring Costs changed N/A year-over-year to $26886.0 in Q4 2015; TTM through Sep 2016 was $26886.0, a N/A change from a year earlier, with the FY2015 full-year figure at $2.5 million, changed N/A from the prior year.
Restructuring Costs for Q4 2015 stood at $26886.0, down from $422482.0 in the prior quarter.
Over the last five years, Restructuring Costs for ALT reached as high as $2.1 million in Q1 2015 and fell as low as $26886.0 in Q4 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Altimmune	346.63 Mn	346.63 Mn	-

Download Data